The global hunter syndrome treatment market is estimated to witness significant growth during the forecast period. Innovative novel therapies in clinical trials and increasing R&D activities by major market players for the development of hunter syndrome treatment are the major two driving factors that are propelling the global hunter syndrome treatment market.

Request a Free Sample of our Hunter Syndrome Treatment Market: https://www.omrglobal.com/request-sample/hunter-syndrome-treatment-market

Few Recent Innovations In The Market-
• In December 2019, Regenxbio’s R&D on gene therapy RGX-121 showed a positive action in the hunter syndrome treatment study. In this study, the company found this gene therapy can decline high levels of heparan sulfate which are associated with neurocognitive by 33% from baseline to week 8. Also, this study found that those patients who progressed beyond week 24 showed stable neurocognitive development. The estimated completion date of this R&D study is December 2022.
• In November 2019, Bioasis announced the allowance of patent applications of xB3 platform in Japan, later in 2020, it allowed patent applications in the US and Europe.
• In June 2019, Denali Therapeutics got approval from the US FDA for DNL310, it is an enzyme replacement therapy for patients with Hunter syndrome.
• In August 2018, ArmaGen received the US Orphan Drug Designation for AGT-184. It is an investigational enzyme replacement therapy (ERT) for the treatment of hunter syndrome treatment. In December 2019, Regenxbio’s R&D on gene therapy RGX-121 showed a positive action in the hunter syndrome treatment study. In this study, the company found this gene therapy can decline high levels of heparan sulfate which are associated with neurocognitive by 33% from baseline to week 8. Also, this study found that those patients who progressed beyond week 24 showed stable neurocognitive development. The estimated completion date of this R&D study is December 2022.
• In February 2018, Inventive announced it shows a positive outcome of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients. This R&D is intended to reduce leukoGAGs enzymes using MPS VI and limited ERT.

A full Report of Hunter Syndrome Treatment Market is Available at: https://www.omrglobal.com/industry-reports/hunter-syndrome-treatment-market

Global Hunter Syndrome Treatment Market Segmentation

By Treatment
• Enzyme Replacement Therapy (ERT)
• Hematopoietic Stem Cell Transplant (HSCT)
• Others ( Gene Therapy, Bone Marrow Transplant, Tonsillectomy)

Global Hunter Syndrome Treatment Market – Segment by Region

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe
Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific
Rest of the World

Company Profiles

• ArmaGen, Inc.
• Bioasis Technologies, Inc.
• Clinigen Group PLC
• Denali Therapeutics, Inc.
• Esteve Pharmaceuticals, S.A.
• GC Pharma Corp.
• Inventiva S.A.
• JCR Pharmaceuticals Co., Ltd.
• REGENXBIO, Inc.
• Sangamo Therapeutics, Inc.
• Shire Plc. (Takeda Pharmaceutical Company)

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/hunter-syndrome-treatment-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404